14 / 39
Volume 4
Nano Research & Applications
ISSN: 2471-9838
Page 73
JOINT EVENT
August 16-18, 2018 | Dublin, Ireland
&
12
th
Edition of International Conference on
Nanopharmaceutics and Advanced Drug Delivery
25
th
Nano Congress for
Future Advancements
Nano Congress 2018
&
Nano Drug Delivery 2018
August 16-18, 2018
Nano Res Appl 2018, Volume 4
DOI: 10.21767/2471-9838-C3-015
Regression of prostate tumors after intravenous administration of targeted gene based nanomedicines
Christine Dufes
University of Strathclyde, UK
T
he possibility of using gene therapy for the treatment of prostate cancer is limited by the lack of safe delivery systems
able to selectively deliver therapeutic genes to tumors by intravenous administration. Given that lactoferrin receptors are
overexpressed on prostate cancer cells, we hypothesized that the conjugation of lactoferrin to generation 3 diaminobutyric
polypropylenimine dendrimer would improve its transfection and therapeutic efficacy in prostate cancer cells. In this study we
demonstrated that the grafting of lactoferrin to the dendrimer led to an enhanced anti-proliferative activity of the dendriplex
by up to 5.8-fold in PC-3 cells compared to the unmodified dendriplex
in vitro
.
In vivo
, the intravenous administration of
lactoferrin-bearing DAB dendriplexes encoding TNFα resulted in the complete suppression of 70% of PC-3 and 50% of DU145
tumors over one month. Treatment with DAB-Lf dendriplex encoding TRAIL led to tumor suppression of 40% of PC-3 tumors
and 20% of DU145 tumors. Tumor suppression was also observed for 20% of both types of prostate tumors following injection
of DAB-Lf dendriplex encoding IL12. The treatment was well tolerated by the animals. Lactoferrin-bearing generation 3
polypropylenimine dendrimer is therefore a highly promising delivery system for the gene therapeutic treatment of prostate
cancer.
C.Dufes@strath.ac.uk